Navigation Links
SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Date:3/27/2008

Company Presents Today at BioCentury Future Leaders Conference

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) is providing an update today on the SGX523 clinical program.

In January 2008, the Company initiated two parallel, multi-center Phase 1 clinical trials of SGX523 in patients with solid tumor cancers. The first trial has been designed to examine twice daily, oral dosing on a continuous 28-day cycle and the second trial has been designed to examine interrupted dosing (a repeating 21 day cycle of 14 days on therapy followed by 7 days off).

In both trials, the Company observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. The interrupted dosing trial started at a higher dose than the continuous dosing trial and no patients are currently receiving treatment on the interrupted dosing trial. In the continuous dosing trial, patients are continuing to be treated at a lower dose level, and the Company is evaluating the safety and efficacy of treatment at that dose level.

"From the initial clinical data, the profile of SGX523 appears to be different than the preclinical data would suggest," said Mike Grey, president and chief executive officer of SGX Pharmaceuticals. "On the continuous dosing trial, patients continue on study at the initial dose and we may explore whether alternative doses and schedules are safe and efficacious. We continue the preclinical development of the BCR-ABL inhibitor SGX393 and the second MET inhibitor SGX126. In addition, we are targeting the identification of two development candidates this year from our drug discovery programs to further enhance our pi
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
4. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
5. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
8. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
9. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
10. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... New York (PRWEB) March 27, 2015 ... the 2015 application period for 43North - the world’s ... prizes, including a grand prize of $1 million, six ... entrepreneurs from around the world to compete for prizes ... funded enterprises in the Western New York region. ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based contract ... executive appointments effective immediately. , Mike Catelani will assume ... of the Board of Directors. Daniel Head is appointed ... will assume the position of Senior Director of Clinical ... (COO), has been appointed to the position of President ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... CHENGDU, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, Co., ... modernized traditional Chinese medicine ("TCM") based in Chengdu, ... and marketing strategy to,categorize both distributors and hospital ... sales and marketing structure. , ...
... File NDA with FDA in Early to Mid-2009 , ... Dec. 2 Strativa Pharmaceuticals, the proprietary products division ... ) today announced that its development partner, MonoSol Rx, ... for a thin film formulation of ondansetron. The ondansetron ...
... Mich., Dec. 2 GeneGo, Inc., the leading ... has become a certified GeneGo Center of Excellence. ... MetaCore data analysis suite, training and advanced support. ... research facility running multiple OMICs experimental studies throughout ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... DETROIT RetroSense Therapeutics, LLC, a Michigan-based ... worldwide option and signed a license agreement for ... Wayne State University,s School of Medicine. ... biology in the School of Medicine, along with ...
... 2011 Acclaimed UC Irvine geneticist Francisco J. Ayala, best ... evolution, will donate $10 million to the School of Biological ... member, will be funded with profits from flourishing vineyards Ayala ... you should do them," said the University Professor and Donald ...
... diverse in the tropical forests of Costa Rica as they are ... forests of Alaska and Sweden. That conclusion is found in ... National Academy of Sciences . Scientists have generally accepted that ... the equator than at the Earth,s poles. But this study ...
Cached Biology News:Wayne State announces license agreement for breakthrough approaches to vision restoration 2Francisco J. Ayala gives $10 million to UCI, largest gift ever by campus faculty member 2From tropics to poles: Study reveals diversity of life in soils 2
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
... (6-28) (human, bovine, porcine, rat) ... (VIP) receptor antagonist. This carboxy-terminal ... be twofold more potent than ... antagonists. Storage: ...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Biology Products: